2023
Title: The role of platelets in immune-mediated inflammatory diseases.
Authors: M. Scherlinger, C. Richez, G.C. Tsokos, Eric Boilard & Patrick Blanco.
doi.org/10.1038/s41577-023-00834-4
A Correction to this paper has been published: https://doi.org/10.1038/s41577-023-00869-7
Title: How I diagnose and treat neonatal thrombocytopenia
Simon J Stanworth, Andrew D Mumford. doi.org/10.1182/blood.2022018017
Title: Childhood outcomes after low-grade intraventricular haemorrhage: A systematic review and meta-analysis.
Philippa Rees, Caitriona Callan, Karan R. Chadda, James Diviney, Fergus Harnden, Julian Gardiner, Cheryl Battersby, Chris Gale, Alastair Sutcliffe
First published: 24 July 2023. https://doi.org/10.1111/dmcn.15713
Title: Identifying Pregnancies at Higher Risk for HPA-1a Alloimmunization and Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT): an International, Prospective, Natural History Study.
Rallybio.com POSTER presented at the 65th American Society of Hematology (ASH) Annual Meeting, December 2023.
December 9, 2023. Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
The Student Voice Prize October 2023 Naitbabies are delighted to be part of The Student Voice Prize 2023. We wish the medical student who we were paired with the very best of luck! The winners and runner ups will be announced on Rare Disease Day 29 February 2024.The Student Voice Prize is an annual, international essay competition that raises the profile of rare diseases within the medical field, particularly with medical students, nurses and scientists who may have never come across rare diseases in their training. Beacon and Medics4RareDiseases host the competition together and the winner gets published in The Orphanet Journal of Rare Diseases!
Title: Fetal and neonatal alloimmune thrombocytopenia: Current pathophysiological insights and perspectives for future diagnostics and treatment.
Stam, W.,Wachholz, G.E.,de Pereda, J.M.,Kapur, R.,van der Schoot, E.,Margadant, C.
Science Direct Blood Reviews volume 59 https://doi.org/10.1016/j.blre.2022.101038
Title: Natural history of human platelet antigen 1a-alloimmunised pregnancies: a prospective observational cohort study.
Thijs W de Vos, MD, Dian Winkelhorst, PhD, Leendert Porcelijn, MD, Mila Beaufort, BSc, Gonda Oldert, BSc, Prof Johanna G van der Bom, MD, et al. The Lancet, October 26, 2023 https://doi.org/10.1016/S2352-3026(23)00271-5
Title: What it’s like when your baby has a rare blood disorder.
A condition called fetal and neonatal alloimmune thrombocytopenia (FNAIT) can be deadly in newborns.
Written By Barbara Brody | November 02, 2023. Johnson & Johnson.
Title: The proportions of term or late preterm births after exposure to early antenatal corticosteroids, and outcomes: systematic review and meta-analysis of 1.6 million infants.
BMJ 2023; 382 doi: https://doi.org/10.1136/bmj-2023-076035
Title: An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study.
April 2023. Journal of Thrombosis and Haemostasis. Volume 1 Issue 4
DOI: https://doi.org/10.1016/j.jtha.2022.11.041
Title: HLA Antibodies in fetal and neonatal alloimmune thrombocytopenia.
Zachary A. Colvin, Jennifer Schiller, Shirng-Wern Tsaih, Ruchika Sharma, Rachael F. Grace, Jennifer J. McIntosh, Brian R. Curtis
First published: 10 April 2023. The journal of AABB Transfusion. https://doi.org/10.1111/trf.17342
Title: A Case of Neonatal Alloimmune Thrombocytopenia Following Maternal Pemphigoid Gestationis.
Danielle A. Chism • Kaila R. Fives • Bailey Beetz • Marc Berger
Published: September 09, 2023. DOI: 10.7759/cureus.44946
Title: Children Newly Diagnosed with Fetal and Neonatal Alloimmune Thrombocytopenia: Neurodevelopmental Outcome at School Age
Thijs W. de Vos, MD. Maud van Zagten, Bsc. Masja de Haas, MD, PhD. Linda S. de Vries, MD, PhD. Enrico Lopriore, MD, PhD. Jeanine M.M. van Klink, PhD.
Open AccessPublished: March 16, 2023. DOI:https://doi.org/10.1016/j.jpeds.2023.02.031
6 March 2023. Latest news on the development of a prophylactic treatment for FNAIT.
NEW HAVEN, Conn.–(BUSINESS WIRE)–Mar. 6, 2023– Rallybio Corporation (Nasdaq: RLYB) today announced that clinical proof-of-concept has been achieved in a Phase 1b study for RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). Results show that one week after a single subcutaneous dose, RLYB212 was able to rapidly and completely eliminate transfused, HPA-1a positive platelets in HPA-1a negative subjects.
